Author

Rui-Rong Xu

h-index 6 View on Semantic Scholar

We have 3 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jul 2026

Natural products in lymphoma therapy: Integrating mechanisms, tumor microenvironment modulation, and translational challenges.

Lymphoma is a heterogeneous group of malignant neoplasms originating from the lymphohematopoietic system, with relapse, drug resistance, and treatment-related toxicity remaining major clinical challenges. Owing to their structural diversity, capacity to modulate multiple signaling nodes, and potential to reshape the tu...

Hangfan Lin, Chunyi Lyu, Teng Wang et al. · European Journal of Pharmaco... · 0 citations

Open access Sep 2026

Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study

Lung and prostate cancers were the most common OPMs in this cohort, highlighting the need for heightened clinical attention to these malignancies in patients with MM.

Chang-Nian Li, Ya-Ru Wang, Lu-Lu Li et al. · Frontiers in Oncology · 0 citations

Open access Aug 2026

Biomarker implications of gene editing in hematologic diseases: latest updates from ASH 2025

Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.

Ze-Zhou Zang, Wei Zheng, Rui-Rong Xu et al. · Biomarker Research · 0 citations